Dyadic International (DYAI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
12 May, 2026Executive summary
The 2026 Annual Meeting will be held virtually on June 18, 2026, with shareholders voting on key proposals including director election, a reverse stock split, auditor ratification, and executive compensation approval.
Shareholders of record as of April 24, 2026, are eligible to vote, with multiple voting methods available including internet, phone, mail, and during the virtual meeting.
Forward-looking statements highlight risks related to Nasdaq compliance, financial performance, and market conditions.
Voting matters and shareholder proposals
Proposals include electing one Class I director for a term ending in 2029, authorizing a reverse stock split (2:1 to 10:1), ratifying Crowe LLP as auditor for 2026, and an advisory vote on executive compensation.
The Board recommends voting FOR all proposals.
Shareholder proposals for the 2027 meeting must be submitted by January 12, 2027, with specific advance notice requirements.
Board of directors and corporate governance
The Board consists of four members, with a classified structure and separation of Chairman and CEO roles.
All directors attended at least 75% of meetings in 2025.
Committees include Audit, Compensation, and Nominating, each with defined charters and independent members.
The Nominating Committee considers a broad range of qualifications for director candidates and accepts shareholder recommendations.
A Code of Conduct and Ethics applies to all directors, officers, and employees.
Latest events from Dyadic International
- Q1 2026 revenue surged 182% to $1.11M, with net loss narrowing and global expansion underway.DYAI
Q1 202613 May 2026 - C1 platform delivers rapid, high-yield, animal-free biologics with proven safety and global validation.DYAI
Investor presentation1 May 2026 - Virtual meeting to vote on director, reverse split, auditor, and executive pay; board urges approval.DYAI
Proxy filing1 May 2026 - Net loss widened to $7.36M on lower revenue, with expanded commercialization and partnerships.DYAI
Q4 202525 Mar 2026 - Commercial product launches and partnerships are driving revenue growth, with more expected by 2027.DYAI
Life Sciences Virtual Investor Forum12 Mar 2026 - Rapid commercialization in non-therapeutic markets targets profitability by 2026.DYAI
Small-Cap Virtual Conference3 Feb 2026 - New partnerships and strong cash position support growth despite lower Q2 revenue.DYAI
Q2 20241 Feb 2026 - Q3 2024 revenue up 5x, net loss narrowed, and cash reserves reached $10M.DYAI
Q3 202414 Jan 2026 - Revenue growth, narrowed losses, and major grants set up multiple product launches in 2025.DYAI
Q4 202419 Dec 2025